Cayman Court Ruling and Appointment of Independent Directors

The Cayman Islands court ruled to strip Seth Harrison, the general partner (GP) of Apple Tree Partners (ATP), a venture capital (VC) firm specializing in the biotech sector, of control over the fund. The court appointed Alexander Lawson and Barry Lynch of Alvarez & Marsal, a global consulting firm, as independent directors to manage the fund. This decision was based on the legal finding that the breakdown of trust between investors and the fund operator had made it impossible to achieve the fund's fundamental objectives. With the management of the USD 3.6 billion fund being transferred, significant changes are expected in the disposal and distribution of portfolio assets.

USD 1.5 Billion Commitment and Legal Dispute Leading to a Breakdown in Trust

The situation originated from a deep conflict between Apple Tree Partners and Rigmora Biotech Investors, its largest investor. Rigmora, a trust owned by the family of Russian billionaire Dmitry Rybolovlev, committed to invest up to USD 1.5 billion in biotech in 2012. However, due to stalled capital inflows, Apple Tree Partners filed a lawsuit in Delaware court, alleging that Rigmora had violated its obligation to contribute USD 97 million. Rigmora, in turn, filed a countersuit in the Cayman Islands court, citing concerns about Harrison's mismanagement. Ultimately, the collapse of fund governance led to judicial enforcement, serving as a warning to the venture investment industry.

Conflict of Jurisdiction Between U.S. Bankruptcy Law and Cayman Islands Ruling

Prior to the Cayman Islands court's ruling, Apple Tree Partners completed a Chapter 11 bankruptcy filing in the U.S. District Court for the District of Delaware to protect its portfolio assets from creditor pressure. Apple Tree Partners maintains that the Cayman Islands court's decision to strip management control is not valid or enforceable in the United States. The U.S. bankruptcy court asserts that it has the sole authority to review Seth Harrison's proposal for funding startups and the asset auction plan until the end of this year. The division of jurisdiction between the United States and the Cayman Islands is leading to increased costs and delays, eroding the value of the fund's assets.

Uncertainty Surrounding Portfolio Pipeline, Including Akero and Red Queen

This dispute is inevitably having a negative impact on the research and development pace of the promising biotech startups that the fund has nurtured. In particular, the value of Akero Therapeutics, which is conducting a Phase 3 clinical trial for efruxifermin, a drug for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and Red Queen Therapeutics, which has completed a Phase 1 clinical trial and is preparing to enter a Phase 2 clinical trial for its COVID-19 treatment candidate, RQ-01, has become more uncertain. In 2023, Intergalactic Therapeutics, which was developing the non-viral gene therapy IG-002, went out of business due to financial difficulties. Therefore, the continuation of clinical trials for portfolio companies depends on the court's prompt approval of asset sales.